Supernus Pharmaceuticals, Inc. (SUPN) Stock Price & How to Invest

Supernus Pharmaceuticals develops and sells prescription medicines for central nervous system conditions: ADHD, epilepsy, Parkinson's disease and, more recently, postpartum depression. The commercial model is straightforward specialty pharma. Supernus owns or licenses the products, runs its own US sales force calling on neurologists and psychiatrists, and books the revenue net of rebates and channel discounts. Its growth engine is Qelbree, a non-stimulant ADHD treatment that did ~$89 million in net sales in the second quarter of 2026 (up ~15%), alongside GOCOVRI for Parkinson's dyskinesia (~$38 million), ONAPGO, a continuous subcutaneous apomorphine infusion launched in 2025 (~$14 million), and collaboration revenue from ZURZUVAE for postpartum depression (~$35 million), which Supernus acquired when it bought Sage Therapeutics in mid-2025 and which it splits 50/50 with Biogen. Working against that are the legacy products: Trokendi XR and Oxtellar XR each fell ~25% year over year, APOKYN fell ~51%, and other older products fell ~71%.

The financial picture as of August 2026 is a company whose reported numbers and adjusted numbers say different things. Second-quarter revenue was ~$219 million, up ~32%, and management raised full-year 2026 guidance to ~$860 million to ~$890 million in revenue and ~$150 million to ~$180 million in adjusted operating earnings. On a GAAP basis the same quarter produced a ~$58 million net loss, driven by a ~$55 million non-cash impairment of the APOKYN intangible plus ~$25 million of ongoing intangible amortization, and the full-year GAAP outlook was cut to an operating loss of ~$20 million to ~$50 million. The balance sheet holds ~$372 million in cash and marketable securities with no meaningful debt at the Supernus level. On top of that sits the August 2026 agreement to merge with Indivior, maker of the opioid-use-disorder treatment SUBLOCADE, in an all-stock deal targeting ~$2.2 billion of combined revenue, ~$888 million of EBITDA and ~$125 million of annual cost synergies, with closing targeted for the fourth quarter of 2026.

The legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue. Qelbree's US new-chemical-entity exclusivity ran out in April 2026 and Supernus received Paragraph IV notices from multiple generic filers in 2025, so the patents running from 2029 to 2035 now have to be defended in court rather than assumed. The merger itself carries real execution risk: it requires shareholder and regulatory approvals, adds leverage through the pre-closing special dividend, and hands Supernus holders a minority position in a business whose largest product serves opioid use disorder, a category with its own reimbursement and legal history. GAAP profitability is currently negative and management's own guidance sees a full-year operating loss, so the ~12x forward earnings multiple rests on adjusted figures that exclude impairments and amortization. Pipeline outcomes have disappointed before, including the SPN-820 miss in treatment-resistant depression in early 2025, and SPN-817 and SPN-820 remain in Phase 2b.

4 analysts publish price targets on SUPN, averaging $62.50 against a $43.25 price as of August 2026, or +44.5%. The published targets run from $55.00 to $67.00, a narrow spread, and the ratings split 3 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SUPN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Supernus Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Qelbree as the volume anchor in ADHD. Qelbree is the largest single product at ~$89 million in quarterly net sales and grew ~15% year over year. The most optimistic published target, $67.00, assumes this works close to its best case.

The case against. The legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue. The most pessimistic target, $55.00, is roughly what SUPN is worth if this bites instead.

Read the full bull and bear case on SUPN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Supernus Pharmaceuticals, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$830M
• Q2 2026 revenue: ~$219M, up ~32% year over year
• FY2026 revenue guidance: ~$860M to ~$890M
• FY2026 adjusted operating earnings guidance: ~$150M to ~$180M
• Net income (TTM): ~-$110M, or ~-$1.91 per share
• Market cap / cash: ~$2.5B market cap, ~$372M cash and marketable securities, no meaningful debt

At ~$43 per share the market values Supernus at roughly 2.4 times enterprise value to 2026 guided revenue and about 12 times forward earnings, which is a discount to profitable specialty pharma peers and reflects both the legacy-product decay and the pending merger. The GAAP loss is largely non-cash: a ~$55 million APOKYN impairment and ~$25 million per quarter of intangible amortization from prior acquisitions sit between adjusted operating earnings of ~$31 million in the quarter and the reported ~$58 million net loss. Because the Indivior exchange ratio is fixed at 1.5401 shares, the practical value of a Supernus share now moves with Indivior's price as much as with Supernus's own results.

Other names that sit close to SUPN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SUPN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SUPN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SUPN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

SUPN is a growing CNS portfolio wrapped in two open questions, whether the new products outrun the legacy decline and whether the Indivior merger delivers the scale and synergies it promises.

Whether SUPN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SUPN a buy or a sell?, and where the stock could go from here in the SUPN stock forecast.

For income investors, whether SUPN pays a dividend and how the payout looks is covered in does SUPN pay a dividend? And to weigh SUPN against a peer, read the full side-by-side comparisons: SUPN vs ABBV and SUPN vs AMRX.